Formic Acid

Formic Acid

SCHEMBL30206367

CNc1nc(Nc2ccc(CN3CCN(C)CC3)cc2)c(C(N)=O)nc1-c1cncc2c1ncn2C.O=CO

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKE Q14164 7/20 0.43
▸ TBK1 Q9UHD2 7/20 0.43
▸ CDK2 P24941 2/20 0.37
▸ AURKA O14965 1/20 0.37
▸ CCNA2 P20248 1/20 0.37
▸ CCNA1 P78396 1/20 0.37
▸ EML4 Q9HC35 3/20 0.37
▸ ALK Q9UM73 3/20 0.37
▸ RET P07949 2/20 0.37
▸ ROS1 P08922 2/20 0.37
▸ FLT3 P36888 2/20 0.37
▸ TNIK Q9UKE5 1/20 0.37
▸ CCNT1 O60563 1/20 0.36
▸ CDK4 P11802 1/20 0.36
▸ CCND1 P24385 1/20 0.36
▸ CDK9 P50750 1/20 0.36
▸ CDK6 Q00534 1/20 0.36
▸ CDK11A Q9UQ88 1/20 0.36
▸ SYK P43405 1/20 0.36
▸ MELK Q14680 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30205589 0.97 IKBKE (0.46) IKBKETBK1CDK2AURKACCNA2
SCHEMBL24943840 0.97 IKBKE (0.46) IKBKETBK1CDK2AURKACCNA2
Formic Acid SCHEMBL30205666 0.95 TBK1 (0.37) IKBKETBK1EML4ALKRET
SCHEMBL24944172 0.92 TBK1 (0.39) IKBKETBK1EML4ALKRET
SCHEMBL24943812 0.90 IKBKE (0.38) IKBKETBK1EML4ALKRET
SCHEMBL30205471 0.90 IKBKE (0.38) IKBKETBK1EML4ALKRET
Formic Acid SCHEMBL30205487 0.90 IKBKE (0.34) IKBKETBK1CDK2AURKACCNA2
Formic Acid SCHEMBL31195388 0.90 IKBKE (0.34) IKBKETBK1CDK2AURKACCNA2
Formic Acid SCHEMBL29173328 0.90 IKBKE (0.34) IKBKETBK1CDK2AURKACCNA2
Formic Acid SCHEMBL29173306 0.90 ABL1 (0.36) IKBKETBK1EML4ALKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 IKBKE 223/4885TBK1 1990/4885CDK2 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback